Orthobiologics Market Size to Record 5.5% CAGR Over 2023-2030; Increasing Launch of Novel Products and Solutions to Strengthen Market Potential

The global orthobiologics market size was valued at USD 8.36 billion in 2022 and is predicted to reach USD 8.77 billion in 2023. The market is anticipated to touch USD 12.78 billion by 2030, recording a CAGR of 5.5% over 2023-2030.

Fortune Business Insights™ presents this information in its latest report titled “Orthobiologics Market Size, Share & COVID-19 Impact Analysis, By Product Type (Viscosupplements, Bone Growth Factors, Demineralized Bone Matrix (DBM), Synthetic Bone Substitutes, Cellular Allograft, Allografts, and Others), By Application (Spinal Fusion, Maxillofacial & Dental, Soft Tissue Repair, Reconstructive & Fracture Surgery, and Others), By End-user (Hospitals & Ambulatory Surgical Centers (ASCs), Specialty Clinics, and Others), and Regional Forecast, 2023-2030”.

Orthobiologics refers to a set of biological substances that are often made from materials naturally found in the body. Also known as regenerative medicine, these substances are used to accelerate the healing process of a wide range of injuries. The growing incidence of bone-related disorders and sports injuries across the world has catalyzed the demand for advanced treatment solutions. This factor is expected to boost the orthobiologics market growth in the coming years.

COVID-19 Pandemic Hampered Market Growth Due to Drop in Patient Visits

The COVID-19 pandemic had a negative influence on the functioning of this market as the number of patients visiting hospitals and other medical centers for treatments decreased considerably. This was due to the imposition of social distancing rules and nationwide lockdowns to mitigate the spread of the virus. Moreover, many essential healthcare resources were reallocated to prioritize the treatment of COVID-19-infected patients. This scenario prompted orthopedic surgeons to push back their surgical appointments, which further slowed the demand for orthobiologics.

Increasing Launch of Novel Products and Solutions to Strengthen Market Potential

Many leading companies operating in this market are realizing the potential of using orthobiologics in the treatment of patients suffering from bone-related ailments, such as osteoarthritis. This factor has prompted them to launch new and advanced orthobiologics products, such as bone growth factors, allograft, and synthetic bone substitutes. Many market leaders are also introducing antibiotic-eluting bone void fillers that can effectively treat bone disorders. Such developments are predicted to strengthen the market’s potential in the coming years.

However, complications related to bone morphogenetic proteins and clinical limitations is set to hinder the market growth.

Orthofix Medical Inc. Announced Merger With SeaSpine to Boost Product Portfolio

Orthofix Medical Inc. announced that it had completed its merger with SeaSpine Holdings Corporation to expand its product range of spinal hardware solutions, biologics, orthopedic solutions, and bone growth therapies. This is set to support and boost the product portfolio of the company which will help the company to maintain its position in the market.

Major Market Players Led the Market With Their Vast Product Portfolios

The competitive landscape of the market is highly fragmented as many of these companies hold a significant share of the market. Medtronic held a dominant share of the global market in 2022 as the company has a vast portfolio of bone graft substitutes. It is also introducing new products in the market to increase its geographical presence, which will further enhance its market dominance.

Notable Industry Development:

June 2023 - Anika Therapeutics, Inc. announced that it had received an additional 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its novel product Tactoset Injectable Bone Substitute.

List of the Companies Profiled in the Report:

• Medtronic (Ireland)


• Zimmer Biomet (U.S.)


• DePuy Synthes (Johnson & Johnson Services, Inc.) (U.S.)


• Stryker (U.S.)


• Anika Therapeutics, Inc. (U.S.)


• SeaSpine (U.S.)


• Bioventus (U.S.)


• RTI Surgical (U.S.)


• MTF Biologics (U.S.)


• Arthrex, Inc. (U.S.)


• Smith & Nephew (U.K.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/orthobiologics-market-100173

Further Report Findings

• North America captured the largest orthobiologics market share in 2022 One of the key factors boosting the regional market’s progress is the growing use of biologics to treat bone-related disorders and injuries and introduction of synthetic substitutes by key companies across the region.


• The market in Asia Pacific is expected to showcase the highest CAGR during the forecast period due to various critical factors. These factors include growing incidence of bone disorders, large patient population, and lack of awareness and adoption of orthobiologic products and solutions in the region’s healthcare sector.


• The spinal fusion application segment dominated the market in 2022 due to the growing incidence of spinal injuries, which has also increased the number of spinal fusion surgeries. Moreover, many leading companies operating in this market are launching novel products and solutions that can be used in various spinal fusion applications.

Table of Segmentation